Minerva Neurosciences Inc (NERV) EPS Estimated At $-0.27

October 8, 2017 - By Vivian Park

 Minerva Neurosciences Inc (NERV) EPS Estimated At $ 0.27

Analysts expect Minerva Neurosciences Inc (NASDAQ:NERV) to report $-0.27 EPS on November, 2.They anticipate $0.03 EPS change or 12.50 % from last quarter’s $-0.24 EPS. After having $-0.27 EPS previously, Minerva Neurosciences Inc’s analysts see 0.00 % EPS growth. The stock decreased 3.21% or $0.25 on October 6, reaching $7.55. About 72,450 shares traded. Minerva Neurosciences Inc (NASDAQ:NERV) has risen 56.56% since October 8, 2016 and is uptrending. It has outperformed by 39.86% the S&P500.

Minerva Neurosciences Inc (NASDAQ:NERV) Ratings Coverage

Among 3 analysts covering Minerva Neurosciences (NASDAQ:NERV), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Minerva Neurosciences had 5 analyst reports since March 9, 2016 according to SRatingsIntel. As per Thursday, June 22, the company rating was maintained by Jefferies. The stock has “Buy” rating by Jefferies on Thursday, May 12. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The firm earned “Buy” rating on Friday, May 27 by Jefferies. The firm has “Buy” rating given on Friday, September 1 by Citigroup.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $320.94 million. The Firm is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. It currently has negative earnings. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

More notable recent Minerva Neurosciences Inc (NASDAQ:NERV) news were published by: Globenewswire.com which released: “Minerva Announces Amended Agreement for MIN-202 in Insomnia” on May 31, 2017, also Seekingalpha.com with their article: “A Deep Dive Into Minerva Neurosciences’ Pipeline” published on May 16, 2017, Fool.com published: “Why Minerva Neurosciences Stock Is Soaring Today” on June 01, 2017. More interesting news about Minerva Neurosciences Inc (NASDAQ:NERV) were released by: Marketwatch.com and their article: “Minerva Neurosciences stock rises 7% on plans to advance schizophrenia drug to …” published on May 15, 2017 as well as Fool.com‘s news article titled: “Why Minerva Neurosciences Inc. Fell 31.1% in July” with publication date: August 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com